CFO
MDGL icon

CVA Family Office’s Madrigal Pharmaceuticals MDGL Stock Holding History

CVA Family Office’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$424 – 1322
2024
Q3 		$424 Hold
2
– – ﹤0.01% 1245
2024
Q2 		$560 Buy
+2
New +$476 ﹤0.01% 1160

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CVA Family Office's MDGL Position: Q4 2024 in Review

CVA Family Office sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 2 shares — an estimated $424 sold.

CVA Family Office first reported a position in MDGL in Q2 2024 and held it in 2 quarters. The position peaked at $560 in Q2 2024. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

  • CVA Family Office reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • CVA Family Office sold 2 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $424.
  • CVA Family Office first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • CVA Family Office's Madrigal Pharmaceuticals position peaked at $560 in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.